ReNeuron Group PLC (LON:RENE) will present new data for its CTX treatment showing what it says is a “significant advance” for the stem cell platform.
The biotech group said the data, to be presented on Wednesday at the Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), shows for the first time that CTX can be used to produce new, non-donor-specific stem cells which are then used to develop therapies for diseases that currently have an unmet medical need.
READ: ReNeuron cell-based treatment hailed by leading non-profit group funding research into treatments for retinal degenerative diseases
Randolph Corteling, ReNeuron’s head of research, said the developments may also allow for the production of “off the shelf” non-donor stem cells, which could serve as an alternative to treatments such as cancer immunotherapies which rely on a patient’s own T-cells (cells in the body which fight illnesses).
The data will be presented at the conference in Barcelona by Steve Pells, ReNeuron’s principal investigator.